Cellular Biomedicine Group (NASDAQ: CBMG) is one of 295 public companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its competitors? We will compare Cellular Biomedicine Group to related companies based on the strength of its profitability, valuation, analyst recommendations, risk, dividends, earnings and institutional ownership.

Volatility & Risk

Cellular Biomedicine Group has a beta of 2.64, meaning that its stock price is 164% more volatile than the S&P 500. Comparatively, Cellular Biomedicine Group’s competitors have a beta of 6.66, meaning that their average stock price is 566% more volatile than the S&P 500.

Institutional and Insider Ownership

5.8% of Cellular Biomedicine Group shares are held by institutional investors. Comparatively, 50.2% of shares of all “Bio Therapeutic Drugs” companies are held by institutional investors. 8.2% of Cellular Biomedicine Group shares are held by company insiders. Comparatively, 17.0% of shares of all “Bio Therapeutic Drugs” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Cellular Biomedicine Group and its competitors top-line revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Cellular Biomedicine Group $229,178.00 -$22.45 million -4.71
Cellular Biomedicine Group Competitors $260.16 million $66.28 million -6.28

Cellular Biomedicine Group’s competitors have higher revenue and earnings than Cellular Biomedicine Group. Cellular Biomedicine Group is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Profitability

This table compares Cellular Biomedicine Group and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cellular Biomedicine Group -12,736.68% -41.33% -39.53%
Cellular Biomedicine Group Competitors -5,486.84% -450.97% -42.10%

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Cellular Biomedicine Group and its competitors, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cellular Biomedicine Group 0 0 1 0 3.00
Cellular Biomedicine Group Competitors 765 3039 11205 227 2.72

Cellular Biomedicine Group presently has a consensus price target of $18.00, indicating a potential upside of 87.50%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 36.82%. Given Cellular Biomedicine Group’s stronger consensus rating and higher possible upside, equities analysts plainly believe Cellular Biomedicine Group is more favorable than its competitors.

Summary

Cellular Biomedicine Group competitors beat Cellular Biomedicine Group on 7 of the 12 factors compared.

Cellular Biomedicine Group Company Profile

Cellular Biomedicine Group, Inc. (CBMG) is a biomedicine company. The Company is engaged in the development of treatments for cancerous and degenerative diseases utilizing cell-based technologies. The Company operates in Biomedicine Cell Therapy segment. The Company’s technology includes platforms, such as Immune Cell therapy for treatment of broad range of cancers using Vaccine, T Cells Receptor (TCR) clonality analysis technology and T Central Memory Cell (Tcm) preparation methodologies, Chimeric Antigen Receptor T cell (CAR-T), and human adipose-derived mesenchymal progenitor cells (haMPC) for treatment of joint and autoimmune diseases, with primary research and manufacturing facilities in China. It is focused on developing and marketing cell-based therapies based on its cellular platforms, to treat serious chronic and degenerative diseases, such as cancer, orthopedic diseases, including osteoarthritis and tissue damage, various inflammatory diseases and metabolic diseases.

Receive News & Stock Ratings for Cellular Biomedicine Group Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellular Biomedicine Group Inc. and related stocks with our FREE daily email newsletter.